COPD heterogeneity: Implications for management

Multidisciplinary Respiratory Medicine

Volumn 11, Issue 1, 2016, Pages

  Barrecheguren, Miriam ^a   Miravitlles, Marc ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EDITORIAL; HUMAN; LUNG EMPHYSEMA; SMOKING;

EID: 85007575294     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/s40248-016-0053-4     Document Type: Editorial

References (12)

1. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785.802.
2. Cooper CB, Barjaktarevic I. A new algorithm for the diagnosis of COPD. Lancet Respir Med. 2015;3:266.8.
3. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598.604.
4. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86.98.
5. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish guideline for COPD (GesEPOC) update 2014. Arch Bronconeumol. 2014;50 Suppl 1:1.16.
6. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128.38.
7. Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med. 2015;21(1):74-9.
8. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroids/long acting β-2 agonist efficacy in COPD. Thorax. 2016;71:118.25.
9. Pascoe S, Locantore N, Dransfield M, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Respir Med. 2015;3:435.42.
10. Barrecheguren M, Roman-Rodriguez M, Miravitlles M. Is a previous diagnosis of asthma a reliable criterion for asthma-COPD overlap sindrome in a patient with COPD? Int J Chron Obstruct Pulmon Dis. 2015;10:1745.52.
11. Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625.37.
12. Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society: a novel phenotypic approach to COPD with patient oriented care. Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:189.201.